Bridge Middle East
Bridge Middle East
Get Consultation
Back to News
HealthTech

BioSapien Doses First Patient in Human Clinical Trial of Biodegradable MediChip™ Cancer Treatment Implant

BridgeMena·
BioSapien Doses First Patient in Human Clinical Trial of Biodegradable MediChip™ Cancer Treatment Implant

BioSapien, an Abu Dhabi-based biotechnology company and Hub71 startup, has dosed its first patient in a first-in-human clinical trial of MediChip™, a biodegradable, 3D-printed medical implant designed to deliver chemotherapy directly to cancer tumours. The milestone marks a significant step in the company's efforts to advance its localized drug-delivery technology into clinical evaluation.

The Phase I study, named OPTIMISE-REFORM, is being conducted at the Burjeel Cancer Institute (BCI) within Burjeel Medical City (BMC) in Abu Dhabi. Its initial objective is to evaluate the safety and tolerability of the investigational treatment in patients with localized rectal cancer.

The technology, known as MediChip-5-FU, is designed to deliver the chemotherapy drug 5-fluorouracil (5-FU) directly to the tumour site through controlled local drug release. Unlike conventional systemic chemotherapy, which distributes medication throughout the body, this localized approach aims to limit drug exposure to healthy tissues while improving the precision of treatment delivery.

The investigational platform is intended to advance more targeted chemotherapy delivery. Longer-term research is also exploring whether localized treatment could support organ preservation and potentially reduce the need for major surgery in selected patients. However, these potential benefits have not yet been clinically established. The current Phase I trial will primarily generate human safety data to inform subsequent development and clinical evaluation.

Commenting on the milestone, Dr. Khatija Ali, Founder and CEO of BioSapien, described the first patient dosing as the culmination of years of scientific development, clinical-grade manufacturing, regulatory preparation and multidisciplinary collaboration.

The clinical investigation is led by Dr. Mohammad Adileh, Principal Investigator and Director of the Surgical Oncology Division at Burjeel Cancer Institute. The study also benefits from the oversight of an independent committee comprising oncology and clinical research experts.

As part of Hub71, BioSapien reflects the continued development of Abu Dhabi's biotechnology ecosystem, which connects emerging healthcare companies with clinical institutions and research partners. This environment supports the advancement of innovative technologies from research and product development towards real-world clinical evaluation.

The milestone also highlights the potential for locally supported biotechnology startups to progress into human clinical trials, contributing to Abu Dhabi's ambitions in advanced healthcare and life sciences.

For BioSapien, the next priority is to establish the safety profile of MediChip™ and generate the clinical evidence required to assess its potential future role in cancer treatment.

 
BioSapienMediChipBiotechnologyInsurTechHealthcare InnovationCancer TreatmentDrug DeliveryClinical TrialsAbu DhabiHub71

You may also like